Holen Sie sich die Stockscreener-App
35.24
3.64%
-1.33
Schlusskurs vom Vortag:
$36.57
Offen:
$36.52
24-Stunden-Volumen:
184.76K
Relative Volume:
0.57
Marktkapitalisierung:
$1.78B
Einnahmen:
$357.71M
Nettoeinkommen (Verlust:
$-20.10M
KGV:
-89.01
EPS:
-0.3959
Netto-Cashflow:
$28.67M
1W Leistung:
-5.27%
1M Leistung:
+10.57%
6M Leistung:
+21.31%
1J Leistung:
+6.72%
1-Tages-Spanne:
$35.21
$36.76
1-Wochen-Bereich:
$35.21
$38.20
52-Wochen-Spanne:
$23.15
$39.33
Immunocore Holdings Plc Adr Stock (IMCR) Company Profile
Firmenname
Immunocore Holdings Plc Adr
Sektor
Branche
Telefon
01235 5430281
Adresse
90 PARK DRIVE, OXFORDSHIRE
Vergleichen Sie IMCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMCR
Immunocore Holdings Plc Adr
|
35.24 | 1.83B | 357.71M | -20.10M | 28.67M | -0.3959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunocore Holdings Plc Adr Stock (IMCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-25 | Fortgesetzt | Jefferies | Buy |
| 2025-05-27 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-11-11 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-10-24 | Eingeleitet | UBS | Sell |
| 2024-10-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-04-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-10-31 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-13 | Eingeleitet | Needham | Buy |
| 2023-08-16 | Eingeleitet | CapitalOne | Overweight |
| 2023-07-17 | Eingeleitet | Canaccord Genuity | Hold |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2023-03-30 | Eingeleitet | Guggenheim | Buy |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2022-12-16 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-30 | Eingeleitet | Barclays | Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2022-09-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2022-08-08 | Eingeleitet | Cowen | Outperform |
| 2022-08-02 | Eingeleitet | BTIG Research | Buy |
| 2022-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-20 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | Goldman | Neutral |
| 2021-03-02 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-02 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Immunocore Holdings Plc Adr Aktie (IMCR) Neueste Nachrichten
Cubist Systematic Strategies LLC Reduces Stock Position in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Given Consensus Rating of “Hold” by Analysts - Defense World
Banque Transatlantique SA Acquires Shares of 10,150 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Morgan Stanley Conference: Strategic Growth and Innovation - Investing.com
Checkpoint Capital L.P. Buys Shares of 9,011 Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Baker BROS. Advisors LP Has $68.91 Million Stock Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore (NASDAQ:IMCR) Stock Price Up 7.4%What's Next? - MarketBeat
Frazier Life Sciences Management L.P. Has $8.94 Million Holdings in Immunocore Holdings PLC Sponsored ADR $IMCR - MarketBeat
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects - Investing.com India
Immunocore at Cantor Global Healthcare: Strategic Focus on 2026 Prospects By Investing.com - Investing.com South Africa
Immunocore Holdings plc ADR (NASDAQ: IMCR) Rises 9.33% In Recent Trading, What’s Next? - stocksregister.com
Immunocore (NASDAQ:IMCR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Earnings call transcript: Immunocore Q2 2025 beats revenue forecast - Investing.com
Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives $58.00 Consensus Price Target from Brokerages - Defense World
Q3 Earnings Estimate for Immunocore Issued By HC Wainwright - Defense World
FY2027 EPS Estimates for Immunocore Boosted by HC Wainwright - Defense World
Immunocore’s SWOT analysis: stock outlook amid clinical milestones, market challenges - Investing.com
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi - sharewise.com
PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues - sharewise.com
Immunocore (IMCR) Q2 Revenue Jumps 30% - The Motley Fool
Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
Immunocore Holdings earnings missed by $0.02, revenue topped estimates - Investing.com South Africa
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut - Yahoo Finance
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut - Yahoo Finance
TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line - sharewise.com
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Immunocore to Report Q2 2025 Financial Results on August 7, 2025 - AInvest
Immunocore stock price target raised to $36 from $33 at Mizuho - Investing.com
Analysts Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) PT at $58.89 - Defense World
Wall Street Analysts See a 72.34% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - Yahoo Finance
The IMCR Stock Puzzle: Unraveling Immunocore Holdings plc ADR’s Fluctuating Performance - investchronicle.com
Can Mizuho Financial Group, Inc. ADR Bounce Back? 52-Week Performance and Analyst Predictions - investchronicle.com
Principal Financial Group Inc. Reduces Stock Holdings in Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) - Defense World
Immunocore Holdings ADR Earns IBD Rating Upgrade - Investor's Business Daily
MBIO Soars on Orphan Drug Nod for Investigational Brain Cancer Therapy - sharewise.com
COGT Stock Soars on Phase III Systemic Mastocytosis Study Success - sharewise.com
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment - Yahoo Finance
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease - Yahoo Finance
Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag - Yahoo Finance
Wall Street Analysts See an 114.35% Upside in Immunocore (IMCR): Can the Stock Really Move This High? - MSN
FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer - Yahoo Finance
FDA Extends INCY's Application for Opzelura Label Expansion - Yahoo Finance
CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech - Yahoo Finance
AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study - Yahoo Finance
SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion - Yahoo Finance
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges By Investing.com - Investing.com South Africa
Immunocore’s SWOT analysis: stock outlook amid pipeline progress, market challenges - Investing.com India
Brokers Set Expectations for Immunocore FY2026 Earnings - Defense World
GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR) - Defense World
Immunocore at Jefferies Global Healthcare Conference: Strong Growth and Promising Trials - Investing.com India
Finanzdaten der Immunocore Holdings Plc Adr-Aktie (IMCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunocore Holdings Plc Adr-Aktie (IMCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Option Exercise |
17.46 |
19,081 |
333,154 |
19,081 |
| Berman David M | HEAD OF R&D |
Sep 10 '25 |
Sale |
36.14 |
31,338 |
1,132,709 |
0 |
| Berman David M | HEAD OF R&D |
Sep 11 '25 |
Sale |
36.28 |
19,081 |
692,259 |
0 |
0.93%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):